U.S. markets open in 2 hours 43 minutes
  • S&P Futures

    3,425.75
    -6.75 (-0.20%)
     
  • Dow Futures

    28,077.00
    -57.00 (-0.20%)
     
  • Nasdaq Futures

    11,671.50
    -19.75 (-0.17%)
     
  • Russell 2000 Futures

    1,604.40
    +1.30 (+0.08%)
     
  • Crude Oil

    40.24
    +0.21 (+0.52%)
     
  • Gold

    1,920.70
    -8.80 (-0.46%)
     
  • Silver

    25.00
    -0.24 (-0.93%)
     
  • EUR/USD

    1.1839
    -0.0028 (-0.24%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.28
    -0.07 (-0.24%)
     
  • GBP/USD

    1.3111
    -0.0033 (-0.25%)
     
  • USD/JPY

    104.6840
    +0.1240 (+0.12%)
     
  • BTC-USD

    12,958.29
    +1,901.28 (+17.20%)
     
  • CMC Crypto 200

    260.53
    +15.64 (+6.39%)
     
  • FTSE 100

    5,765.33
    -11.17 (-0.19%)
     
  • Nikkei 225

    23,474.27
    -165.19 (-0.70%)
     

DarioHealth: Q2 Earnings Insights

Benzinga Insights
·1 min read

Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 423.08% year over year to ($0.68), which beat the estimate of ($1.40).

Revenue of $1,787,000 up by 8.24% from the same period last year, which beat the estimate of $1,550,000.

Outlook

DarioHealth hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 12, 2020

View more earnings on DRIO

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/36466

Technicals

52-week high: $18.84

52-week low: $0.20

Price action over last quarter: Up 123.19%

Company Profile

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.